Memantin je lek iz adamantanske klase lekova za tretiranje Alchajmerove bolesti koji deluje na glutamatergični sistem putem blokiranja NMDA glutamatnih receptora. On je prvi put sintetisan u kompaniji Eli Lili1968. Memantin je u prodaju pod imenima Aksura, Akatinol, Namenda, Ebiksa, Abiksa i Memoks. Uprkos dugogodišnjeg istraživanja, postoji malo dokaza da ima uticaja na blagu do umerene Alchajmerovu bolest.[6]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID21948594.edit
↑Schneider, LS; Dagerman, KS, Higgins, JP, McShane, R (2011). „Lack of evidence for the efficacy of memantine in mild Alzheimer disease.”. Archives of neurology68 (8): 991–8. PMID21482915.
Lipton SA (2005). „The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism”. Current Alzheimer research2 (2): 155–65. DOI:10.2174/1567205053585846. PMID15974913.
Y
